Ind Swift Laboratories has provided clarification to BSE Limited regarding a sudden surge in trading volume, attributing the market activity to its recent arbitration award disclosure. The pharmaceutical company successfully concluded arbitration proceedings with PI Industries Limited, with the Arbitral Tribunal rejecting all claims from both parties.

BSE Surveillance Response

The company responded to BSE's inquiry dated April 9, 2026, regarding the unusual spike in share trading volume. Ind-Swift Laboratories confirmed that it has consistently disclosed all material information affecting company operations and performance in accordance with regulatory requirements.

The company stated it is not aware of any specific reason for the sudden volume surge except for the arbitration award disclosure made on April 7, 2026. Management emphasized that the trading activity appears purely market-driven and may result from various factors including prevailing market conditions.

Arbitration Award Details

The Arbitral Tribunal constituted by Mumbai Centre for International Arbitration (MCIA) delivered its final order on April 7, 2026. The tribunal comprehensively rejected all claims filed by PI Industries Limited as the claimant, while simultaneously dismissing all counterclaims submitted by Ind Swift Laboratories Limited and other respondents.

Regulatory Compliance

Ind-Swift Laboratories fulfilled its disclosure obligations under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The company provided comprehensive details about the arbitration conclusion to both BSE Limited and National Stock Exchange of India Limited within stipulated timeframes.

The company reiterated its commitment to maintaining full compliance with SEBI Listing Regulations, 2015, and other applicable laws. All material information bearing on company operations and performance continues to be disclosed within required timelines.

Company Operations

Ind-Swift Laboratories Limited operates as a pharmaceutical company with its registered office in Chandigarh. The company maintains manufacturing facilities across two strategic locations - Unit I in Punjab and Unit II in Jammu & Kashmir. The successful arbitration conclusion removes any potential financial liability or uncertainty associated with the dispute, allowing focused attention on core pharmaceutical operations without pending legal proceedings overhang.

Ind-Swift Laboratories Limited has announced the opening of a special window for re-lodgement of transfer requests of physical shares and dematerialisation, in compliance with SEBI regulations. The pharmaceutical company published newspaper advertisements on April 5, 2026, informing shareholders about this important facility.

Regulatory Compliance and Timeline

The special window has been established pursuant to SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026. This initiative aims to facilitate investors in gaining rightful access to their securities that were traded in physical form.

Shareholder Assistance and Process

Eligible shareholders seeking to utilise this facility can contact the company through multiple channels for assistance within the stipulated timeframe. The company has designated specific contact points to ensure smooth processing of requests.

Contact Information

Registrar and Share Transfer Agent (RTA):

• Email: rta@alankit.com
• Office: Alankit House, 4E/2 Jhandewalan Extension, New Delhi - 110 055
• Phone: 011-42541234

Company Direct Contact:

• Email: investor@indswiftlabs.com

Transfer Requirements and Documentation

Shareholders must fulfil specific requirements when lodging transfer requests with the RTA. The process has been designed to ensure compliance with current regulations while facilitating smooth conversion to dematerialised form.

Mandatory Requirements:

• Active demat account
• Client Master List (CML)
• Original transfer documents
• Physical share certificates

All transferred shares will be issued exclusively in dematerialised form once the RTA verifies and approves all submitted documents.

Newspaper Publication Details

The company fulfilled its regulatory obligations under Regulation 47 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, by publishing advertisements in leading newspapers.

This special window represents an important opportunity for shareholders holding physical securities to convert them to dematerialised form, ensuring better liquidity and easier transfer processes in line with current market practices.